DeepMed Research

TG THERAPEUTICS

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1993-01-01

Employees: 264

Market Cap: $3.5B

Website: http://www.tgtherapeutics.com

Clinical Trials

Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)

Phase 2

Terminated

Conditions: Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions: Drug: Ublituximab
Drug: Umbralisib
Drug: Venetoclax

First Posted Date: 2019-01-11

Last Posted Date: 2024-04-19

Lead Sponsor: TG Therapeutics, Inc.

Target Recruit Count: 277

Registration Number: NCT03801525

Locations: 🇺🇸
TG Therapeutics Investigational Trial Site, Seattle, Washington, United States
🇺🇸
TG Therapeutics Investigational Site, Louisville, Kentucky, United States

Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma

Phase 1

Terminated

Conditions: B-cell Non Hodgkin Lymphoma
Richter's Transformation

Interventions: Drug: Cosibelimab
Drug: Cosibelimab + Ublituximab + Bendamustine combination

First Posted Date: 2018-12-19

Last Posted Date: 2022-08-22

Lead Sponsor: TG Therapeutics, Inc.

Target Recruit Count: 18

Registration Number: NCT03778073

Locations: 🇺🇸
TG Therapeutics Investigational Trial Site, Seattle, Washington, United States

Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies

Phase 1

Terminated

Conditions: Non Hodgkin Lymphoma
Chronic Lymphocytic Leukemia

Interventions: Drug: TG-1701
Drug: Umbralisib
Biological: Ublituximab

First Posted Date: 2018-09-14

Last Posted Date: 2024-07-19

Lead Sponsor: TG Therapeutics, Inc.

Target Recruit Count: 172

Registration Number: NCT03671590

Locations: 🇵🇱
TG Therapeutics Investigational Trial Site, Wrocław, Poland

An Extension of the TG1101-RMS201 Trial

Phase 2

Completed

Conditions: Relapsing Remitting Multiple Sclerosis

Interventions: Biological: Ublituximab

First Posted Date: 2017-12-21

Last Posted Date: 2022-12-21

Lead Sponsor: TG Therapeutics, Inc.

Target Recruit Count: 48

Registration Number: NCT03381170

Locations: 🇺🇸
TG Therapeutics Investigational Trial Site, San Antonio, Texas, United States

Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL

Phase 1

Terminated

Conditions: Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma

Interventions: Drug: Venetoclax
Drug: Umbralisib
Biological: Ublituximab
Drug: Lenalidomide

First Posted Date: 2017-12-20

Last Posted Date: 2022-08-22

Lead Sponsor: TG Therapeutics, Inc.

Target Recruit Count: 78

Registration Number: NCT03379051

Locations: 🇺🇸
TG Therapeutics Investigational Trial Site, Cleveland, Ohio, United States

Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Marginal Zone Lymphoma
Non Follicular Indolent Non-Hodgkin Lymphoma
Waldenstrom Macroglobulinemia

Interventions: Drug: Umbralisib

First Posted Date: 2017-12-06

Last Posted Date: 2023-06-23

Lead Sponsor: TG Therapeutics, Inc.

Target Recruit Count: 21

Registration Number: NCT03364231

Locations: 🇺🇸
TG Therapeutics Investigational Trial Site, New York, New York, United States

Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )

Phase 3

Completed

Conditions: Relapsing Multiple Sclerosis (RMS)

Interventions: Biological: Ublituximab
Drug: Teriflunomide
Drug: Oral Placebo
Drug: IV Placebo

First Posted Date: 2017-09-11

Last Posted Date: 2021-12-06

Lead Sponsor: TG Therapeutics, Inc.

Target Recruit Count: 549

Registration Number: NCT03277261

Locations: 🇺🇸
TG Therapeutics RMS Investigational Site, Round Rock, Texas, United States
🇺🇸
TG Therapeutics RMS Investigational Trial Site, Dallas, Texas, United States

Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)

Phase 3

Completed

Conditions: Relapsing Multiple Sclerosis (RMS)

Interventions: Biological: Ublituximab
Drug: Teriflunomide
Drug: Oral Placebo
Drug: IV Placebo

First Posted Date: 2017-09-11

Last Posted Date: 2021-12-06

Lead Sponsor: TG Therapeutics, Inc.

Target Recruit Count: 545

Registration Number: NCT03277248

Locations: 🇺🇸
TG Therapeutics RMS Investigational Trial site, Seattle, Washington, United States
🇺🇸
TG Therapeutics RMS Investigational Trial Site, Pittsburgh, Pennsylvania, United States

Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials

Phase 2

Terminated

Conditions: Chronic Lymphocytic Leukemia
Non Hodgkin Lymphoma

Interventions: Drug: TGR-1202
Drug: TGR-1202 + Ublituximab

First Posted Date: 2017-07-02

Last Posted Date: 2022-07-21

Lead Sponsor: TG Therapeutics, Inc.

Target Recruit Count: 51

Registration Number: NCT03207256

Locations: 🇺🇸
TG Therapeutics Investigational Site, Canton, Ohio, United States
🇺🇸
TG Therapeutics Investigational Trial Site, Milwaukee, Wisconsin, United States

Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma

Phase 2

Terminated

Conditions: Marginal Zone Lymphoma
Follicular Lymphoma
Diffuse Large B-Cell Lymphoma
Mantle Cell Lymphoma
Small Lymphocytic Lymphoma

Interventions: Biological: Ublituximab
Drug: Umbralisib
Biological: Bendamustine

First Posted Date: 2016-06-08

Last Posted Date: 2022-07-21

Lead Sponsor: TG Therapeutics, Inc.

Target Recruit Count: 710

Registration Number: NCT02793583

Locations: 🇬🇧
TG Therapeutics Investigational Trial Site, Plymouth, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy